Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
09:16am, Tuesday, 28'th Apr 2026
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.16 per share a year ago.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
05:13pm, Wednesday, 22'nd Apr 2026
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 202
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average – Time to Sell?
03:20am, Tuesday, 21'st Apr 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.67 and traded
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Increase in Short Interest
02:20am, Wednesday, 15'th Apr 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 5,310,26
Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)
01:09am, Tuesday, 14'th Apr 2026
Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Atrinsic (NASDAQ: PTIX - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two com
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
11:02am, Thursday, 09'th Apr 2026
WASHINGTON, April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification.
WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the preven
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving Average – Should You Sell?
03:20am, Tuesday, 07'th Apr 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.51 and traded
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
04:34pm, Thursday, 19'th Mar 2026
WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, toda
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of “Moderate Buy” from Analysts
04:28am, Monday, 16'th Mar 2026
Shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the stock, Market
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
08:01am, Tuesday, 03'rd Mar 2026
WASHINGTON, March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a for
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
04:35pm, Thursday, 26'th Feb 2026
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug
10:56am, Wednesday, 25'th Feb 2026
Vanda Pharmaceuticals (NASDAQ: VNDA) shares are up during Wednesday's premarket session following the FDA's approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, as well
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics Li
